Post-COVID pulmonary fibrosis, which involves scarring of the lungs that can worsen over time and may require a lung ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

A discovery about how severe COVID-19 damages lung cells suggests that an existing drug could treat lingering respiratory ...